DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW
Based on 1 Customer Validation
DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW is a polypeptide targeting tenascin-X (Tenascin-X) that can be conjugated with liposomes and exosomes. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW specifically binds to Tenascin-X on the surface of cardiomyocytes, mediates receptor-dependent uptake of nanocarriers, enhances targeted drug delivery of cargo to cardiomyocytes, and increases drug accumulation in cardiac tissue. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW protects cardiomyocytes treated with LPS, alleviates oxidative stress, repairs mitochondrial function, inhibits ferroptosis and apoptosis, and downregulates the secretion of pro-inflammatory cytokines at the same time. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW improves cardiac injury and pathological morphology in mice with sepsis-induced cardiomyopathy, restores GPX4 expression, and promotes the internalization of cardiomyocyte-derived exosomes, making it suitable for related research on sepsis-induced cardiomyopathy, myocardial ischemia-reperfusion injury, and other conditions.
For research use only. We do not sell to patients.
- Purity: 95.0%
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
|
GPX4 |
DSPE-PEG-CMP-EXO (20 μM miR302 mimic; 30 min loading incubation, 0-72 h stability testing, 1-48 h release quantification) efficiently encapsulates 20 μM miR302 mimic, protects miR302 for 24 h in serum-containing medium, and achieves 90% cumulative release of miR302 within 48 h[2].
DSPE-PEG-CMP-miR302-EXO (6 h hypoxia, 16 h reperfusion) significantly upregulates miR302 expression, increases Ki67 and Yap protein levels, and enhances proliferation of H9C2 cardiomyocytes exposed to in vitro ischemia/reperfusion injury[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 8-10 weeks old, 20-25 g, left anterior descending coronary artery ligated for 60 minutes followed by reperfusion)[2]
-
Dosage:0.25 μg (DSPE-PEG-CMP) per mouse
-
Administration:i.v.; every 2 days; 4 weeks
-
Result:Showed minimal to no significant improvement in serum levels of cardiac injury markers (cTnI, CKMB) and proinflammatory factors (TNF-α, IL-1β) compared to the model group.
Showed no significant reduction in cardiomyocyte necrosis, structural disorder, or myocardial apoptosis rate compared to the model group.
Showed no significant improvement in left ventricular ejection fraction (EF), fractional shortening (FS), LV Mass Index, LVAWd, LVAWs, LV VOLd, LV VOLs, LVIDd, LVIDs, LVPWd, or LVPWs compared to the model group.
Chemical Information
-
Appearance Solid
-
Color White to off-white
-
SMILES
[O-]P(OCCNC(OCCOCC(N[C@@H](CC1=CNC2=CC=CC=C21)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N3CCC[C@H]3C(N[C@H](C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@@](C(NCC(N[C@H](C(N[C@@H](C(O)=O)CC4=CNC5=CC=CC=C54)=O)CO)=O)=O)([H])[C@H](O)C)=O)=O)CCC/N=C(N)\N)=O)CC(C)C)=O)C)=O)CCCNC(N)=N)=O)C(C)C)=O)([H])[C@@H](C)O)=O)C(C)C)=O)C(C)C)=O)=O)=O)C)=O)CCC(O)=O)=O)CO)=O)CC(C)C)=O)=O)=O)(OC[C@](COC(CCCCCCCCCCCCCCCCC)=O)(OC(CCCCCCCCCCCCCCCCC)=O)[H])=O.[n]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)